Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol. 2014;35(2):88-93.
Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and
immunity. J Clin Invest. 2016;126(7):2404-2411.
Corrales L, Gajewski TF. Molecular pathways: targeting the stimulator of interferon genes (STING) in the
immunotherapy of cancer. Clin Cancer Res. 2015;21(21):4774-4779.
Woo S-R, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune
recognition of immunogenic tumors. Immunity. 2014;41(5):830-842.
Curran E, Chen X, Corrales L, et al. STING pathway activation stimulates potent immunity against acute
myeloid leukemia. Cell Rep. 2016;15(11):2357-2366.
Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads
to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018-1830.
Woo S-R, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends
Immunol. 2015;36(4):250-256.
Ohkuri T, Ghosh A, Kosaka A, et al. STING contributes to anti-glioma immunity via triggering type-I IFN
signals in the tumor microenvironment. Cancer Immunol Res. 2014;2(12):1199-1208.
Swann JB, Hayakawa Y, Zerafa N, et al. Type I IFN contributes to NK cell homeostasis, activation, and
antitumor function. J Immunol. 2007;178(12):7540-7549.
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev
Immunol. 2015;15(7):405-414.
Gaidt MM, Ebert TS, Chauhan D, et al. The DNA inflammasome in human myeloid cells is initiated by a
STING-cell death program upstream of NLRP3. Cell. 2017;171(5):1110-1124.
Song S, Peng P, Tang Z, et al. Decreased expression of STING predicts poor prognosis in patients with
gastric cancer. Sci Rep. 2017;7:39858. doi:10.1038/srep39858.
Xia T, Konno H, Ahn J, Barber GN. Deregulation of STING signaling in colorectal carcinoma constrains DNA
damage responses and correlates with tumorigenesis. Cell Rep. 2016;14(2):282-297.
Xia T, Konno H, Barber GN. Recurrent loss of STING signaling in melanoma correlates with susceptibility to
viral oncolysis. Cancer Res. 2016;76(22):6747-6759.
Fu J, Kanne DB, Leong M, et al. STING agonist formulated cancer vaccines can cure established tumors
resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52. doi:10.1126/scitranslmed.aaa4306.
Ghaffari A, Peterson N, Khalaj K, et al. STING agonist therapy in combination with PD-1 immune checkpoint
blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer.
2018;119(4):440-449.